• news.cision.com/
  • H. Lundbeck A/S/
  • Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Report this content

Valby, Denmark, 7 February 2024 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.

1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Johan Luthman
2. Reason for the notification
a) Position/status Executive Vice President, Research & Development
b) Initial notification/Amendment Initial notification
3. Details of  the issuer,  emission  allowance  market participant,
auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial
instrument, type of instrument

Identification code
SharesA-shares: DK0061804697B-shares: DK0061804770
b) Nature of the transaction Other transaction (vesting of Restricted Shares in accordance with long-term incentive program)
c) Price(s) and volume(s) Price(s) Volume(s)
DKK 0 A-shares: 6,737B-shares: 26,945
d) Aggregated information
- Aggregated volume
- Price
e) Date of the transaction 2024-02-07
f) Place of the transaction NASDAQ Copenhagen XCSE

1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Jacob Tolstrup
2. Reason for the notification
a) Position/status Executive Vice President, Commercial Operations
b) Initial notification/Amendment Initial notification
3. Details of  the issuer,  emission  allowance  market participant,
auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial
instrument, type of instrument

Identification code
SharesA-shares: DK0061804697B-shares: DK0061804770
b) Nature of the transaction Other transaction (vesting of Restricted Shares in accordance with long-term incentive program)
c) Price(s) and volume(s) Price(s) Volume(s)
DKK 0 A-shares: 6,396B-shares: 25,583
d) Aggregated information
- Aggregated volume
- Price
e) Date of the transaction 2024-02-07
f) Place of the transaction NASDAQ Copenhagen XCSE

1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Keld Flintholm Jørgensen
2. Reason for the notification
a) Position/status Executive Vice President, Corporate Strategy & Business Development
b) Initial notification/Amendment Initial notification
3. Details of  the issuer,  emission  allowance  market participant,
auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial
instrument, type of instrument

Identification code
SharesA-shares: DK0061804697B-shares: DK0061804770
b) Nature of the transaction Other transaction (vesting of Restricted Shares in accordance with long-term incentive program)
c) Price(s) and volume(s) Price(s) Volume(s)
DKK 0 A-shares: 4,913B-shares: 19,649
d) Aggregated information
- Aggregated volume
- Price
e) Date of the transaction 2024-02-07
f) Place of the transaction NASDAQ Copenhagen XCSE

1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Lars Bang
2. Reason for the notification
a) Position/status Executive Vice President, Product Development & Supply
b) Initial notification/Amendment Initial notification
3. Details of  the issuer,  emission  allowance  market participant,
auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial
instrument, type of instrument

Identification code
SharesA-shares: DK0061804697B-shares: DK0061804770
b) Nature of the transaction Other transaction (vesting of Restricted Shares in accordance with long-term incentive program)
c) Price(s) and volume(s) Price(s) Volume(s)
DKK 0 A-shares: 6,626B-shares: 26,504
d) Aggregated information
- Aggregated volume
- Price
e) Date of the transaction 2024-02-07
f) Place of the transaction NASDAQ Copenhagen XCSE

Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities means inter alia:

  • spouse or cohabitant
  • dependent children
  • legal entities in which the executive has a controlling influence




Lundbeck contacts

Investors:                                    Media:
Palle Holm Olesen Thomas Mikkel Mortensen
Vice President, Investor Relations Media Relations Lead, Corporate Communication
PALO@lundbeck.com THMR@lundbeck.com
+45 30 83 24 26 +45 30 83 30 24
Sophia Nørskov Bech
Senior Manager, Investor Relations
SONQ@lundbeck.com
+45 30 83 24 60


About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases. As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options. Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we

serve and the communities we are part of.

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

H. Lundbeck A/S

Ottiliavej 9, 2500 Valby, Denmark

+45 3630 1311

info@lundbeck.com

Subscribe